Inclusion Criteria:

- Males age 18-80 years

- Histologic diagnosis of adenocarcinoma of the prostate

- Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy

- Detectable metastases by bone scan, CT scan or MRI

- Two consecutive rising PSA values obtained at least two weeks apart and both obtained
at least 4-6 weeks after discontinuation of hormone therapy. Second PSA value must be
> 5.0 ng/mL. LHRH agonist should not be discontinued.

- Testosterone < 50 ng/dL. Must have had orchiectomy or is currently receiving an LHRH
agonist.

- WBC > 3.0 x 109/L, ANC > 1.5 x 109/L, hemoglobin > 6.2 mmol/L, and platelets > 100 x
109/L

- Serum creatinine < 177 umol/L Bilirubin < 1.5 times the upper limit of normal AST < 3
times the upper limit of normal

- ECOG performance status 0-2

- Life expectancy of at least 6 months

- If sexually active, willing to use barrier contraception during the treatment phase
of the protocol

- The ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

- Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer

- Bone pain severe enough to require routine narcotic analgesia use

- Clinical evidence of brain metastases or history of brain metastases

- Seropositive for HIV, Hepatitis B antigen positive and/or Hepatitis C viremic

- Prior chemotherapy or immunotherapy for prostate cancer

- Radiation therapy within 4 weeks of the first treatment

- Surgery within 4 weeks of the first treatment. Must have recovered from all side
effects.

- Flutamide within 4 weeks of the first treatment Megesterol acetate (Megace),
finasteride (Proscar), bicalutamide (Casodex),nilutamide, aminoglutethimide,
ketoconazole or diethylstilbestrol within 6 weeks of the first treatment.

- Systemic corticosteroid use within 4 weeks of the first treatment

- History of autoimmune disease

- History of another malignancy, except for the following: adequately treated basal
cell or squamous cell skin cancer, superficial bladder cancer, adequately treated
Stage I or II cancer currently in complete remission or any other cancer that has
been in complete remission for at least 5 years